The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial.
Evanthia Galanis
No relevant relationships to disclose
Jann Nagina Sarkaria
No relevant relationships to disclose
S. Keith Anderson
No relevant relationships to disclose
Wenting Wu
No relevant relationships to disclose
Kurt A. Jaeckle
No relevant relationships to disclose
Caterina Giannini
No relevant relationships to disclose
Jan C. Buckner
No relevant relationships to disclose
Patrick Y. Wen
Honoraria - Merck
Research Funding - Merck